Precision medicine has demonstrated clinical utility and cost-effectiveness, which is why many believe this approach will be key to value-based cancer care in the future, said Jonathan Hirsch, founder and president of Syapse.
Precision medicine has demonstrated clinical utility and cost-effectiveness, which is why many believe this approach will be key to value-based cancer care in the future, said Jonathan Hirsch, founder and president of Syapse.
Transcript (slightly modified)
How can physicians use precision medicine to improve outcomes and reduce cost?
Precision medicine, we think, is one of the key elements to helping us all achieve the vision of value-based care. And the reason that I say that is because in a value-based paradigm you prize improved outcomes and you prize cost savings rather than revenue enhancing, and precision medicine is a key way to achieve that.
So we have partnered with Intermountain Healthcare over the past few years on precision oncology initiatives, and this culminated in a study that Intermountain published earlier this year in JOP [Journal of Oncology Practice], which demonstrated an improval in progression-free survival, approximately a doubling in PFS, and a net neutral impact on total cost of care when moving stage IV patients from a standard of care-based approach to a precision medicine approach. Specifically, to genomic profiling of their tumor and targeted therapeutic options, mostly commercially available drugs used on- and off-label.
This approach was dramatic for a health system to demonstrate the clinical utility as well as the cost effectiveness. So we really think that precision medicine is the future of cancer care, and we look forward to democratizing access for many health systems.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More